Impact Biomedical (IBO) Receivables - Other (2023)

Impact Biomedical's (IBO) quarterly Receivables - Other came in at $128000.0 in Q4 2023, up 36.17% on a QoQ basis from $94000.0 in Q2 2023.

Impact Biomedical (IBO) Receivables - Other (2023) Analysis & Trends

Impact Biomedical (IBO) has 1 years of Receivables - Other data on file, last reported at $128000.0 in Q4 2023.

Quarterly Receivables - Other changed N/A year-over-year to $128000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $128000.0 (changed N/A YoY) and the FY2024 annual result came in at -$128000.0, down 200.0% from the prior year.
Receivables - Other grew to $128000.0 in Q4 2023, from $94000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $128000.0 in Q4 2023 to a low of $94000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Impact Biomedical	49.54 Mn	49.53 Mn	2,000.00

Download Data